CDKN2A and pancreatic intraductal papillary-mucinous neoplasm: In a recent study, Basturk and coworkers reported the analysis of the molecular abnormalities occurring in 22 IPTN tumors, showing that: most of the previously-reported IPMN genetic abnormalities were absent; loss of CDKN2A was observed in 25% of cases; MAPK genes were not frequently altered; chromatin remodeling genes (such as MLL1, MLL2, MLL3, BAP1) were altered in 32% of cases; PI3K pathway genes were altered in 27% of cases; finally, 18% of tumors displayed FGFR2 fusions [71].